Topical tacrolimus and the 308-nm excimer laser: A synergistic combination for the treatment of vitiligo

Archives of Dermatology

Volumn 140, Issue 9, 2004, Pages 1065-1069

  Passeron, Thierry ^a   Ostovari, Nima ^a   Zakaria, Wassim ^a   Fontas, Eric ^a   Larrouy, Jean Claude ^a   Lacour, Jean Philippe ^a   Ortonne, Jean Paul ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EXCIMER LASER; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MONOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; REPIGMENTATION; SIDE EFFECT; SKIN DEFECT; SKIN PIGMENTATION; ULTRAVIOLET RADIATION; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASER THERAPY, LOW-LEVEL; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROBABILITY; PROSPECTIVE STUDIES; RADIATION DOSAGE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; VITILIGO;

EID: 4544301752     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.9.1065     Document Type: Article

References (16)

1. Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol. 1996;35:895-898.
2. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148:373-374.
3. Mofty ME, Zaher H, Esmat S, et al. PUVA and PUVB in vitiligo-are they equally effective? Photodermatol Photoimmunol Photomed. 2001;17:159-163.
4. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999-1003.
5. Taneja A. Treatment of vitiligo. J Dermatolog Treat. 2002;13:19-25.
6. Horio T. Indications and action mechanisms of phototherapy. J Dermatol Sci. 2000;23(suppl 1):S17-S21.
7. Baltas E, Nagy P, Bonis B, et al. Repigmentation of localized vitiligo with the xenon chloride laser. Br J Dermatol. 2001;144:1266-1267.
8. Baltas E, Csoma Z, Ignacz F, Dobozy A, Kemeny L. Treatment of vitiligo with the 308-nm xenon chloride excimer laser. Arch Dermatol. 2002;138:1619-1620.
9. Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser: a pilot study. J Am Acad Dermatol. 2002;46:727-731.
10. Taneja A, Trehan M, Taylor CR. 308-nm excimer laser for the treatment of localized vitiligo. Int J Dermatol. 2003;42:658-662.
11. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581-585.
12. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis. 2003;71:158-162.
13. Novak Z, Bonis B, Baltas E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67:32-38.
14. Tanghetti EA, Gillis PR. Clinical evaluation of B Clear and Protopic treatment for vitiligo [abstract]. Lasers Surg Med. 2003;32:37.
15. Tran C, Lubbe J, Sorg O, Carraux P, Didierjean L, Saurat J. Topical tacrolimus decreases UVB-induced DNA damage in mouse skin. J Invest Dermatol. 2003;121:P1072.
16. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol. 1998;134:1532-1540.